In the past week, RZLT stock has gone down by -6.44%, with a monthly gain of 7.11% and a quarterly surge of 22.22%. The volatility ratio for the week is 3.99%, and the volatility levels for the last 30 days are 3.04% for Rezolute Inc. The simple moving average for the past 20 days is -2.74% for RZLT’s stock, with a -8.25% simple moving average for the past 200 days.
Is It Worth Investing in Rezolute Inc (NASDAQ: RZLT) Right Now?
The 36-month beta value for RZLT is at 1.04. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RZLT is 70.56M, and currently, shorts hold a 6.28% of that float. The average trading volume for RZLT on June 19, 2025 was 1.11M shares.
RZLT) stock’s latest price update
The stock price of Rezolute Inc (NASDAQ: RZLT) has dropped by -1.45 compared to previous close of 4.13. Despite this, the company has seen a fall of -6.44% in its stock price over the last five trading days. globenewswire.com reported 2025-05-28 that Target enrollment exceeded with 62 participants enrolled, including approximately 15 percent from U.S. sites Topline data is anticipated in December of 2025 REDWOOD CITY, Calif., May 28, 2025 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced that enrollment is complete in the sunRIZE study, a global, Phase 3 multicenter, double-blind, randomized, placebo-controlled, parallel arm study designed to evaluate the efficacy and safety of ersodetug for the treatment of hypoglycemia in patients with congenital HI.
Analysts’ Opinion of RZLT
Many brokerage firms have already submitted their reports for RZLT stocks, with Wedbush repeating the rating for RZLT by listing it as a “Outperform.” The predicted price for RZLT in the upcoming period, according to Wedbush is $12 based on the research report published on November 05, 2024 of the previous year 2024.
Guggenheim, on the other hand, stated in their research note that they expect to see RZLT reach a price target of $11. The rating they have provided for RZLT stocks is “Buy” according to the report published on August 27th, 2024.
BTIG Research gave a rating of “Buy” to RZLT, setting the target price at $13 in the report published on July 17th of the previous year.
RZLT Trading at 9.10% from the 50-Day Moving Average
After a stumble in the market that brought RZLT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.20% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RZLT starting from Hogenhuis Wladimir, who purchase 6,758 shares at the price of $2.92 back on Mar 31 ’25. After this action, Hogenhuis Wladimir now owns 84,025 shares of Rezolute Inc, valued at $19,733 using the latest closing price.
Elam Nevan C, the CEO of Rezolute Inc, purchase 12,302 shares at $2.85 during a trade that took place back on Mar 27 ’25, which means that Elam Nevan C is holding 224,119 shares at $34,999 based on the most recent closing price.
Stock Fundamentals for RZLT
Current profitability levels for the company are sitting at:
- -984.88 for the present operating margin
- 0.88 for the gross margin
The net margin for Rezolute Inc stands at -1258.59. The total capital return value is set at -0.68. Equity return is now at value -95.15, with -80.01 for asset returns.
Based on Rezolute Inc (RZLT), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -36.96.
Currently, EBITDA for the company is -68.42 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 5780.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.43.
Conclusion
In conclusion, Rezolute Inc (RZLT) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
